Horizon Therapeutics Public Limited (NASDAQ:HZNP) Shares Purchased by Van ECK Associates Corp

Van ECK Associates Corp boosted its holdings in Horizon Therapeutics Public Limited (NASDAQ:HZNPGet Rating) by 41.1% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 15,904 shares of the biopharmaceutical company’s stock after acquiring an additional 4,636 shares during the quarter. Van ECK Associates Corp’s holdings in Horizon Therapeutics Public were worth $984,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. Envestnet Asset Management Inc. increased its position in Horizon Therapeutics Public by 6.5% in the 2nd quarter. Envestnet Asset Management Inc. now owns 289,477 shares of the biopharmaceutical company’s stock valued at $23,089,000 after acquiring an additional 17,612 shares during the period. FDx Advisors Inc. increased its position in shares of Horizon Therapeutics Public by 4.6% during the 2nd quarter. FDx Advisors Inc. now owns 15,999 shares of the biopharmaceutical company’s stock valued at $1,276,000 after purchasing an additional 705 shares during the period. Advisors Asset Management Inc. increased its position in shares of Horizon Therapeutics Public by 41.6% during the 2nd quarter. Advisors Asset Management Inc. now owns 2,767 shares of the biopharmaceutical company’s stock valued at $221,000 after purchasing an additional 813 shares during the period. Steward Financial Group LLC acquired a new position in shares of Horizon Therapeutics Public during the 2nd quarter valued at $41,000. Finally, Mirae Asset Global Investments Co. Ltd. increased its position in shares of Horizon Therapeutics Public by 0.6% during the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 85,614 shares of the biopharmaceutical company’s stock valued at $9,008,000 after purchasing an additional 538 shares during the period. 91.01% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Horizon Therapeutics Public

In related news, EVP Jeffrey W. Sherman sold 28,352 shares of Horizon Therapeutics Public stock in a transaction on Monday, December 12th. The stock was sold at an average price of $111.45, for a total transaction of $3,159,830.40. Following the completion of the sale, the executive vice president now owns 54,501 shares of the company’s stock, valued at $6,074,136.45. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In related news, EVP Jeffrey W. Sherman sold 5,187 shares of the stock in a transaction that occurred on Friday, January 6th. The stock was sold at an average price of $113.29, for a total value of $587,635.23. Following the transaction, the executive vice president now owns 49,314 shares in the company, valued at $5,586,783.06. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Jeffrey W. Sherman sold 28,352 shares of the stock in a transaction that occurred on Monday, December 12th. The stock was sold at an average price of $111.45, for a total value of $3,159,830.40. Following the completion of the transaction, the executive vice president now owns 54,501 shares in the company, valued at approximately $6,074,136.45. The disclosure for this sale can be found here. Insiders sold a total of 36,907 shares of company stock valued at $4,128,218 over the last quarter. Company insiders own 2.50% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have recently issued reports on HZNP shares. Jefferies Financial Group lifted their price target on Horizon Therapeutics Public from $101.00 to $125.00 in a research report on Thursday, December 1st. Piper Sandler cut Horizon Therapeutics Public from an “overweight” rating to a “neutral” rating in a research report on Monday, December 12th. TheStreet upgraded Horizon Therapeutics Public from a “c+” rating to a “b-” rating in a research report on Tuesday, November 22nd. HC Wainwright started coverage on Horizon Therapeutics Public in a research report on Tuesday, November 1st. They set a “neutral” rating and a $74.00 price target on the stock. Finally, BMO Capital Markets cut Horizon Therapeutics Public from an “outperform” rating to a “market perform” rating in a report on Tuesday, December 13th. Eight analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat.com, Horizon Therapeutics Public presently has an average rating of “Hold” and a consensus target price of $111.42.

Horizon Therapeutics Public Stock Performance

Shares of Horizon Therapeutics Public stock opened at $113.24 on Monday. The stock has a market cap of $25.66 billion, a PE ratio of 46.41, a price-to-earnings-growth ratio of 1.74 and a beta of 1.16. The business has a fifty day simple moving average of $98.48 and a 200-day simple moving average of $79.22. The company has a quick ratio of 3.74, a current ratio of 3.96 and a debt-to-equity ratio of 0.51. Horizon Therapeutics Public Limited has a 12 month low of $57.84 and a 12 month high of $117.49.

Horizon Therapeutics Public (NASDAQ:HZNPGet Rating) last issued its earnings results on Wednesday, November 2nd. The biopharmaceutical company reported $1.25 EPS for the quarter, topping the consensus estimate of $1.00 by $0.25. The business had revenue of $925.36 million during the quarter, compared to analysts’ expectations of $888.93 million. Horizon Therapeutics Public had a return on equity of 24.59% and a net margin of 15.51%. On average, sell-side analysts anticipate that Horizon Therapeutics Public Limited will post 4.23 EPS for the current fiscal year.

Horizon Therapeutics Public Profile

(Get Rating)

Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. The company operates in two segments, Orphan and Inflammation.

See Also

Want to see what other hedge funds are holding HZNP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Horizon Therapeutics Public Limited (NASDAQ:HZNPGet Rating).

Institutional Ownership by Quarter for Horizon Therapeutics Public (NASDAQ:HZNP)

Receive News & Ratings for Horizon Therapeutics Public Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Therapeutics Public and related companies with MarketBeat.com's FREE daily email newsletter.